Evidence map›Paper›PMID 31496590›Full record

ArticleIndian journal of surgical oncology2019

Elevated Neutrophil-Lymphocyte Ratio in Luminal-Type Locally Advanced Breast Cancer to Circumvent Neo-Adjuvant Chemotherapy.

Joseph Sushil Rao, Harish Kumar Hanumappa, Elvis Peter Joseph, Raghunandan Gorantlu Chowdappa, Rakesh Ramesh

Open access · greenAbstract read
In one paragraph

Article in Indian journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joseph Sushil RaoDepartment of Surgical Oncology, St. John's National Academy of Health Sciences, Bangalore, India.ORCID 0000-0002-0197-6107
Harish Kumar HanumappaDepartment of Surgical Oncology, St. John's National Academy of Health Sciences, Bangalore, India.
Elvis Peter JosephDepartment of Surgical Oncology, St. John's National Academy of Health Sciences, Bangalore, India.
Raghunandan Gorantlu ChowdappaDepartment of Surgical Oncology, St. John's National Academy of Health Sciences, Bangalore, India.
Rakesh RameshDepartment of Surgical Oncology, St. John's National Academy of Health Sciences, Bangalore, India.
St. John's National Academy of Health Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophil-Lymphocyte Ratio (NLR) provides an understanding of the systemic inflammatory conditions. NLR plays an important role as a predictor of mortality in breast and other malignancies. The application of NLR to predict prognosis of Locally Advanced Breast Cancer (LABC) has not been well developed. In this retrospective study, we establish a relationship of pre-treatment NLR with the Pathological Complete Response (pCR) in LABC patients to enhance decision-making and treatment protocols. Data of women diagnosed with carcinoma breast between January 2015 and December 2017 was retrieved from hospital records of a tertiary medical centre in Bangalore, India, after obtaining institutional ethical clearance. LABC patients were categorized into pCR(+) and pCR(-). NLR was calculated and divided into quartiles. The cutoff NLR was determined using the Receiver Operating Characteristic (ROC) curve. Statistical analysis was performed on 119 LABC patients, of which 25 (21%) achieved pCR. Oestrogen Receptor (ER) positivity was significantly lower in pCR(+) than in pCR(-) (

Indexed as

Locally advanced breast cancerLuminal stagingNACTNeutrophil-Lymphocyte Ratio

Identifiers

PMID31496590
PMCPMC6708037
OpenAlexW2950301487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.